The Correlation of initial hematological feature with advanced stage in Chronic Lymphocytic Leukemia in Kurdistan Region of Iraq

Tavan Ismael Mahmood

doi:10.21271/ZJPAS.33.5.12

Authors

Tavan Ismael Mahmood MBChB, KBMS-candidate, Department of Hematology, Hiwa Cancer hospital, Sulaymaniyah, Kurdistan Region, Iraq,

DOI:

https://doi.org/10.21271/ZJPAS.33.5.12

Keywords:

Chronic lymphocytic leukemia; Initial laboratory; advanced stage, KRI.

Abstract

Chronic lymphocytic leukemia (CLL) is considered by an accumulation of matured lymphocytes in the blood, bone marrow, spleen. And lymph .We aimed to find the correlation of initial hematological feature with advanced stage in CLL. Methods: A retrospective study was conducted on 138 patients with CLL, confirmed by flow cytometry of peripheral blood collected in Hiwa Hematological and Oncological Hospital in Sulaimani, Nanakaly Hospital in Hawler, and Azadi Hematology - Oncology Center in Duhok, Kurdistan Region of Iraq dated from January 1, 2010, to December 31, 2020. Results: The mean age of 63.07±11 years with male predominance. The majority of patients at presentation were Rai Stage II and Binet stage A. The frequency of DAT positivity was found in (6.5%), which also established appositive relationship with advanced stage, there were statistically significant relation of hemoglobin level, platelet counts, LDH level to Rai stage and Binet stage disease (P value <0.001), No association were noted between different age groups and initial laboratory finding, also no relation of gender to staging. Conclusion: In the present study there was a significant relation between laboratory findings (hemoglobin, platelet count, LDH levels) to with staging, in addition DAT positivity demonstrated a significant correlation with advanced stage, those with High LDH levels associated with more advanced Rai stage.

References

Abbas, S. A. et al. (2015) ‘Direct coombs test positivity in B-chronic lymphoid leukemia: A marker of advanced clinical disease’, Asian Pacific Journal of Cancer Prevention, 16(14), pp. 6007–6010. doi: 10.7314/APJCP.2015.16.14.6007.

Al-rubaie, H. A. and Mohammed, S. J. (2018) ‘Assessment of Interleukin-8 in Patients with Chronic Lymphocytic Leukemia in Correlation with the Prognostic Factors : β2 -microglobulin , LDH and Binet Stage’, 17(2).

Autore, F. et al. (2019) ‘Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12’, Cancers, 11(7), pp. 1–12. doi: 10.3390/cancers11070896.

Basabaeen, A. A. et al. (2019) ‘Clinical presentation and hematological profile among young and old chronic lymphocytic leukemia patients in Sudan’, BMC Research Notes, 12(1), pp. 12–17. doi: 10.1186/s13104-019-4239-7.

Brander, D. M. et al. (2017) ‘Welcome & Introductions Living with Chronic Lymphocytic Leukemia ( CLL )’, (Cll), pp. 1–43.

Cantú, E. S. et al. (2013) ‘Male-to-female sex ratios of abnormalities detected by fluorescence in situ hybridization in a population of chronic lymphocytic leukemia patients’, Hematology Reports, 5(1), pp. 13–17. doi: 10.4081/hr.2013.e4.

Dearden, C. et al. (2008) ‘The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: A beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia’, Blood, 111(4), pp. 1820–1826. doi: 10.1182/blood-2007-07-101303.

Faria, J. R. de et al. (2000) ‘Prognosis related to staging systems for chronic lymphocytic leukemia’, Sao Paulo Medical Journal, 118(4), pp. 83–88. doi: 10.1590/S1516-31802000000400002.

Haider, M. S. et al. (2019) ‘Autoimmune cytopenias in chronic lymphocytic leukemia’, Pakistan Journal of Medical Sciences, 35(5), pp. 1334–1338. doi: 10.12669/pjms.35.5.369.

Hallek, M. et al. (2018) ‘iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL’, Blood, 131(25), pp. 2745–2760. doi: 10.1182/blood-2017-09-806398.

Hasan, K. M. (2018) ‘Clinical aspects, immunophenotypic analysis and survival rate of chronic lymphocytic leukaemia patients in Erbil city, Iraq’, Sultan Qaboos University Medical Journal, 18(4), pp. e461–e467. doi: 10.18295/squmj.2018.18.04.006.

Kanti RR, Stilgenbauer S and Aster JC (2019) ‘Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma - UpToDate [Internet] Updated May 2019’, pp. 1–36. Available at: https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma.

Kyasa, M. J. et al. (2003) ‘Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma’, American Journal of Hematology, 74(1), pp. 1–8. doi: 10.1002/ajh.10369.

Li, H. et al. (2017) ‘Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: A retrospective analysis of prognostic factors in China’, Chinese Journal of Cancer Research, 29(2), pp. 156–165. doi: 10.21147/j.issn.1000-9604.2017.02.09.

Madu, A. J. et al. (2019) ‘Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria’, Malawi Medical Journal, 31(2), pp. 144–149. doi: 10.4314/mmj.v31i2.7.

Mercer, R. (2002) ‘Review articles’, The Antiquaries Journal, 82, pp. 358–365. doi: 10.1017/S000358150007390X.

Moreno, C. et al. (2010) ‘Autoimmune cytopenia in chronic lymphocytic leukemia: Prevalence, clinical associations, and prognostic significance’, Blood, 116(23), pp. 4771–4776. doi: 10.1182/blood-2010-05-286500.

Mozaheb, Z., NazarAbadi, M. H. H. and Aghaee, M. A. (2012) ‘Chronic lymphocytic leukemia and prognostic factors’, Asian Pacific Journal of Cancer Prevention, 13(7), pp. 3009–3013. doi: 10.7314/APJCP.2012.13.7.3009.

Naji, A. S. (2012) ‘Outcome of 49 Iraqi adult patients with Chronic Lymphocytic Leukemia treated with oral alkylating agent’:, مجلة كلية الطب, 54(2), pp. 126–130. doi: 10.32007/jfacmedbagdad.v2126-130.

Ochoa-garcía, P. P. et al. (2019) ‘Association between the phenotype of the blood group system AB0 and’, 30(4), pp. 639–644.

Parikh, S. A. et al. (2014) ‘Chronic lymphocytic leukemia in young (≤ 55 years) patients: A comprehensive analysis of prognostic factors and outcomes’, Haematologica, 99(1), pp. 140–147. doi: 10.3324/haematol.2013.086066.

Payandeh, M., Sadeghi, E. and Sadeghi, M. (2015) ‘Survival and clinical aspects for patients with chronic lymphocytic leukemia in Kermanshah, Iran’, Asian Pacific Journal of Cancer Prevention, 16(17), pp. 7987–7990. doi: 10.7314/APJCP.2015.16.17.7987.

Pflug, N. et al. (2014) ‘Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia’, Blood, 124(1), pp. 49–62. doi: 10.1182/blood-2014-02-556399.

Pulte, D. et al. (2016) ‘Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century’, Journal of Hematology and Oncology, 9(1), pp. 1–8. doi: 10.1186/s13045-016-0257-2.

Rodrigues, C. A. et al. (2016) ‘Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia’, Revista Brasileira de Hematologia e Hemoterapia, 38(4), pp. 346–357. doi: 10.1016/j.bjhh.2016.07.004.

Rosenquist, R. et al. (2013) ‘Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: Where do we stand?’, Leukemia and Lymphoma, 54(11), pp. 2351–2364. doi: 10.3109/10428194.2013.783913.

Sagatys, E. M. and Zhang, L. (2012) ‘Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia’, Cancer Control, 19(1), pp. 18–25. doi: 10.1177/107327481201900103.

Ward, J. H. (2001) ‘Autoimmunity in chronic lymphocytic leukemia.’, Current treatment options in oncology, 2(3), pp. 253–257. doi: 10.1007/s11864-001-0039-z.

Yun, X., Zhang, Y. and Wang, X. (2020) ‘Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia’, Biomarker Research, 8(1), pp. 1–11. doi: 10.1186/s40364-020-00222-3.